HeartBeam, Inc.
HeartBeam, Inc. is a U.S. medical technology company developing a portable, cable-free ECG platform that captures cardiac signals in three dimensions and synthesizes a 12-lead ECG. Its system is designed for ambulatory use outside the hospital, with an initial focus on arrhythmia assessment and longer-term expansion into broader cardiac monitoring and heart-attack detection.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaPortable, credit-card-sized ECG recording devices used by patients outside a healthcare facility.
Software that converts 3D cardiac signals into a synthesized 12-lead ECG for clinical interpretation.
Patient and physician-facing applications that support data capture, review, and clinical use.
Studies, reference-site development, and educational support used to drive adoption and reimbursement.
Asiakkaat
HeartBeam sells into clinical users rather than mass consumer channels, with early targets including concierge practices, preventative cardiology groups, cardiology departments in hospitals, and hospital-at-home programs. Healthcare insurers are also an important eventual customer because the company is trying to prove that its system can lower downstream costs and support coverage decisions.
Buy the system to give patients access to a medical-grade ECG outside the clinic and to support premium care workflows.
Use the device for ambulatory monitoring and diagnostic support where a standard 12-lead ECG is not practical.
Adopt the product for remote cardiac assessment in home-based care settings.
May reimburse the system if HeartBeam proves clinical benefit and cost-effectiveness.
Use the platform in studies where portable, high-fidelity ECG data is needed.
Strategia
HeartBeam’s strategy is to build clinical evidence first, then use that evidence to support commercial adoption and eventual payer reimbursement. Near term, it is focusing on a narrow launch with a small direct sales effort, reference sites, and early access feedback; longer term, it wants to expand into heart-attack detection, extended-wear monitoring, and partnering opportunities.
Adoption depends on proving the system is clinically credible and usable in real-world settings.
A small number of credible clinical sites can accelerate trust and reduce sales complexity.
Coverage would materially expand addressable demand and improve economics.
Broader product functionality and licensing can extend the technology beyond the initial device launch.
Maantiede
HeartBeam’s initial commercial focus is the United States, where it has already run multicenter clinical studies and received FDA clearance for its system. The company says it will remain opportunistic internationally, and it already has a small patent footprint outside the U.S. in South Korea, Germany, France, the Netherlands, and the United Kingdom.
Riskit
HeartBeam is still in an early commercialization stage, so its business depends on successful clinical validation, regulatory execution, and eventual market adoption. It also faces financing risk because it has required repeated equity funding, and competition is intense from much larger device and consumer wearable companies with established customer bases.
- Additional capital requirementVaikutus: KorkeaTodennäköisyys: Korkea
The company expects to need more funding to complete development and support growth, which could be dilutive or unavailable.
Kohdistuu - Reimbursement and market adoption riskVaikutus: KorkeaTodennäköisyys: Korkea
Initial targets may buy outside reimbursement, but broader scale likely requires payer coverage and proof of cost-effectiveness.
Kohdistuu - Regulatory and clinical trial riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Commercialization depends on FDA clearance and continued positive clinical evidence; setbacks would delay launch and adoption.
Kohdistuu: 12L synthesis software and future product claims
- Competitive pressureVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Apple, AliveCor, Google and other medtech firms have greater resources, brand recognition, and distribution.
Kohdistuu: Ambulatory ECG and cardiac monitoring market
- Cybersecurity and data integrityVaikutus: KeskitasoTodennäköisyys: Kohtalainen
The product handles sensitive health data, and breaches or data corruption could harm operations and reputation.
Kohdistuu: Patient data and cloud/workflow systems
Kirjanpito
Harkinnanvaraiset erätExpense is measured using option-pricing assumptions and recognized over vesting, so changes in estimates can move reported losses.
Vaikutus: Affects operating expense and net loss
Management reassesses the probability and timing of regulatory milestones, which can change compensation expense recognition.
Vaikutus: Can accelerate or defer equity compensation expense
Once commercialization begins, the company will need to determine timing of device, software, and service revenue recognition.
Vaikutus: Will affect revenue timing and gross margin presentation
The company has funded operations through equity sales, which affects share count, cash flow, and per-share metrics.
Vaikutus: Dilution and financing cash flow
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
HeartSciences Inc.
HSCSW · Finance Services
Heartflow, Inc.
HTFL · Surgical & Medical Instruments & Apparatus
iRhythm Holdings, Inc.
IRTC · Surgical & Medical Instruments & Apparatus
Odyssey Health, Inc.
ODYY · Surgical & Medical Instruments & Apparatus
BioCardia, Inc.
BCDA · Biological Products, (No Diagnostic Substances)
Adagio Medical Holdings, Inc.
ADGM · Surgical & Medical Instruments & Apparatus
Päivitetty: 24.9.2026